Lisa Svartdal Normann

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Epidermal Growth Factor Receptor

High Throughput

Endoplasmic Reticulum Stress

Top Venues

Breast cancer (Dove Medical Press)

This page only lists publications with an associated author ORCID identifier.

Publications

Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Mælandsmo
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. PloS one 18 (1) (2023)
Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Mælandsmo
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. PloS one 18 (1) (2023)
Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Mælandsmo
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. PloS one 18 (1) (2023)
Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Mælandsmo
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. PloS one 18 (1) (2023)
Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Mælandsmo
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. PloS one 18 (1) (2023)
Lisa Svartdal Normann, Mads Haugland Haugen, Miriam Ragle Aure, Vessela N Kristensen, Gunhild Mari Mælandsmo, Kristine Kleivi Sahlberg
miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy. Breast cancer (Dove Medical Press) 14 (2022)